UK markets open in 4 hours 8 minutes

CHEMOMETEC A/S (CHEMM.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
459.80+17.20 (+3.89%)
At close: 04:59PM CET
Full screen
Previous close442.60
Open448.00
Bid460.60 x 0
Ask459.80 x 0
Day's range444.00 - 465.00
52-week range255.00 - 539.50
Volume76,223
Avg. volume88,859
Market cap8.002B
Beta (5Y monthly)1.26
PE ratio (TTM)55.53
EPS (TTM)8.28
Earnings date08 May 2024
Forward dividend & yield6.00 (1.30%)
Ex-dividend date13 Oct 2023
1y target est451.67
  • Globe Newswire

    Interim report for the first half of 2023/24 – Correction

    ANNOUNCEMENT NO. 250 5 February 2024 Interim report for the first half of 2023/24 – Correction In connection with the previously published interim report for the first half of 2023/24 (announcement no. 249), there were errors in the sales and operating results highlights: EBITDA for the second quarter fell by 36% to DKK 93.1 million, and the EBITDA margin was 48%, compared with 63% in the year-earlier period. EBITDA for the first half fell by 36% to DKK 145.2 million, and the EBITDA margin was 4

  • Globe Newswire

    Interim report 2023/24 - Full-year guidance maintained despite continued challenging market conditions

    ANNOUNCEMENT NO. 249 5 February 2024 Interim report for the first half of 2023/24 Full-year guidance maintained despite continued challenging market conditions Rasmus Kofoed, CEO: “Rasmus Kofoed, CEO: “In the second quarter, we saw early signs of market conditions improving within our key market area, cell-based therapy, but the investment climate remains subdued. Our revenue therefore continued to be under pressure, as expected, declining 15% year-on-year to DKK 108.1 million. Lower sales of in

  • GlobeNewswire

    Martin Glensbjerg takes up new position at ChemoMetec

    ANNOUNCEMENT NO. 248 20 December 2023 Martin Glensbjerg takes up a new role in ChemoMetec COO and deputy chairman of the board Martin Glensbjerg has decided to step down in ChemoMetec to pass the baton on to the next generation. From 1 February 2024 until the end of 2024, he will act as Senior Advisor with reference to CEO Rasmus Kofoed. Martin Glensbjerg continues as deputy chairman of the board. In his new role, Martin Glensbjerg will, among other things, participate in the update of ChemoMete